DDInter280 DDInter992
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus, [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes. Cardiovascular disease is the most common cause of death in these patients.
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Labetalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylpropanolamine
Phenylpropanolamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Labetalol
Labetalol {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Labetalol {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Labetalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Isoxsuprine (Compound)
Canagliflozin (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine (Compound) resembles Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine (Compound) resembles Ephedrine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Canagliflozin (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Labetalol (Compound) and Labetalol (Compound) resembles Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Isoxsuprine (Compound)
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Isoxsuprine (Compound)